Drug Trial Radar · NCT05605093
Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)
Last checked: Nov 20, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
602
Actual
Start
Dec 23, 2022
Primary completion
Oct 28, 2025
Study completion Oct 28, 2025
Sponsor
- Lead sponsor
- University of MinnesotaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institute of Allergy and Infectious Diseases (NIAID)
- First posted
- Nov 4, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Treatments are needed to improve outcomes among patients hospitalized for COVID-19, including direct-acting antiviral (DAA) agents to mitigate the pathology driven by ongoing viral replication. This trial will evaluate S-217622 (ensitrelvir), an anti-SARS-CoV2 3C-like protease inhibitor (PI) developed by Shionogi \&; Co. Ltd. The study design is a randomized, placebo-controlled, multi-center international clinical trial that will evaluate the clinical efficacy of ensitrelvir when given in addition to standard of care (SOC) for inpatients with COVID-19. The SOC will be determined by local established guidelines and may include additional DAA (e.g., remdesivir) and immunomodulatory treatment strategies. Certain SOC treatments will be pre-specified prior to randomization.
Conditions
- COVID-19
Interventions
Shionogi Protease Inhibitor (S-217622)Drug
S-217622 (ensitrelvir) is an oral anti-SARS-CoV2 PI that does not require ritonavir co-administration The dose is 375/125 (375 mg on Day 0, followed by 125 mg daily on Days 1-4).
placeboDrug
Placebo is an oral tablet administered once (3 tabs) on Day 0 and once (1 tab) daily on days 1-4, 5-day course.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Recovered by Day 60Time frame: Through Day 60
Locations
187 sites in 24 countries. Site status is shown where the registry gives one.
University of Alabama Birmingham University Hospital (Site 213-002)
Birmingham, Alabama
Banner University Medical Center Tucson (Site 206-004)
Tucson, Arizona
Southern Arizona VA Healthcare System (Site 074-009)
Tucson, Arizona
UCSF Fresno (Site 203-005)
Fresno, California
VA Loma Linda Healthcare System (Site 074-017)
Loma Linda, California
MemorialCare Health System (Site 066-003
Long Beach, California
VA Long Beach Healthcare System (Site 074-026)
Long Beach, California
Cedars-Sinai Medical Center (Site 208-002)
Los Angeles, California
Ronald Reagan UCLA Medical Center (Site 203-002)
Los Angeles, California
VA Northern California Health Care System (Site 074-023)
Mather, California
Hoag Memorial Hospital Presbyterian (Site 080-026)
Newport Beach, California
Veterans Affairs Palo Alto Health Care System (VAPAHCS) (Site 074-005)
Palo Alto, California
UC Davis Health (Site 203-004)
Sacramento, California
VA San Diego Healthcare System (Site 074-016)
San Diego, California
Zuckerberg San Francisco General Hospital and Trauma Center (Site 213-007)
San Francisco, California
UCSF Medical Center at Mount Zion (203-007)
San Francisco, California
San Francisco VAMC (Site 074-002)
San Francisco, California
University of California San Francisco (Site 203-001)
San Francisco, California
Stanford University Hospital & Clinics (Site 203-003)
Stanford, California
Lundquist Institute for Biomedical Innovation (Site 066-002)
Torrance, California
Rocky Mountain Regional VA Medical Center (Site 074-010)
Aurora, Colorado
University of Colorado Hospital (Site 204-001)
Aurora, Colorado
Public Health Institute at Denver Health (Site 017-004)
Denver, Colorado
Yale University (Site 025-001)
New Haven, Connecticut
MedStar Health Research Institute/MedStar Washington Hospital Center (Site 009-021)
Washington D.C., District of Columbia
Washington DC VA Medical Center (Site 009-004)
Washington D.C., District of Columbia
University of Florida - Gainesville (Site 201-004)
Gainesville, Florida
Miami VA Healthcare System (Site 074-003)
Miami, Florida
Orlando VA Medical Center (Site 074-032)
Orlando, Florida
Tampa General Hospital (032-001)
Tampa, Florida
John H. Stroger, Jr. Hospital of Cook County (Site 080-046)
Chicago, Illinois
University of Illinois at Chicago (Site 008-012)
Chicago, Illinois
Carle Foundation Hospital (Site 080-049)
Urbana, Illinois
Lutheran Medical Group (Site 301-010)
Fort Wayne, Indiana
The University of Kansas Hospital (Site 080-044)
Kansas City, Kansas
University of Kentucky (Site 210-004)
Lexington, Kentucky
NIH Clinical Center (Site 080-043)
Bethesda, Maryland
Massachusetts General Hospital (202-002)
Boston, Massachusetts
Beth Israel Deaconess Medical Center (Site 202-001)
Boston, Massachusetts
Baystate Medical Center (Site 201-001)
Springfield, Massachusetts
Showing 40 of 187 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.